Gene expression profiles in BCL11B-siRNA treated malignant T cells

Area of Science:

• Molecular Biology
• Cancer Genomics

Background:

• The B-cell chronic lymphocytic leukemia (BCL11B) gene plays a crucial role in T-cell development.
• Downregulation of BCL11B using small interfering RNA (siRNA) induces apoptosis in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.

Purpose of the Study:

• To investigate the molecular mechanisms underlying BCL11B-siRNA-mediated growth inhibition and apoptosis in T-ALL.
• To identify global gene expression changes in response to BCL11B knockdown.

Main Methods:

• Global gene expression profiling using microarray analysis in BCL11B-siRNA treated Molt-4 cells.
• Validation of key gene expression changes using real-time PCR in Molt-4 cells and primary T-ALL samples.

Main Results:

• Microarray analysis revealed 142 upregulated and 109 downregulated genes in BCL11B-siRNA treated Molt-4 cells.
• Pro-apoptotic genes (TNFSF10, BIK, BNIP3) were upregulated, and an anti-apoptotic gene (BCL2L1) was downregulated.
• Genes involved in the transforming growth factor-beta (TGF-β) pathway, SPP1 and CREBBP, showed significant downregulation, though CREBBP validation was inconsistent.

Conclusions:

• BCL11B-siRNA treatment significantly alters the expression profiles of TNFSF10, BCL2L1, and SPP1.
• These gene expression changes were observed in both the Molt-4 T-ALL cell line and primary T-ALL cells.
• The findings provide insights into the molecular pathways affected by BCL11B inhibition in T-ALL.